Autobio Diagnostics is set to exit the molecular diagnostic test provider through a purchase by women’s health-focused technology provider Hologic.

Women-focused medical technology producer Hologic has agreed to acquire Mobidiag, a Finland-headquartered molecular diagnostics technology developer backed by clinical diagnostics product maker Autobio Diagnostics, for €668m ($795m). The deal, which is expected to close in the fourth quarter of the 2021 fiscal year, involves a cash payment of $714m combined with $81m of net debt…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.